Evidence map›Paper›PMID 41066778›Full record

SynthesisUltrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology2026

Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus: systematic review and meta-analysis of clinical outcomes from non-randomized studies.

N Salmeri, A Pizzetti, E Grassi, R Cioffi, G Mangili, M Seckl, A Sotiriadis, M Candiani, P I Cavoretto

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

N SalmeriObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-3239-3799
A PizzettiObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
E GrassiObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
R CioffiObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0003-4370-8271
G MangiliObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-8451-429X
M SecklGestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London, UK.
A SotiriadisSecond Department of Obstetrics and Gynecology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0003-0876-5596
M CandianiObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
P I CavorettoObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0001-8097-366X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveComplete hydatidiform mole and coexisting normal fetus (CHMCF) is a rare condition for which there is significant heterogeneity in diagnosis, counseling and management of complications. The objective of this study was to summarize the prevalence of clinical outcomes in reported cases of CHMCF.

methodsA systematic literature search was conducted in PubMed, Embase and Scopus databases from inception until 1 October 2024. Case series and cohort studies including at least three cases of histologically confirmed CHMCF were included. A random-effects model was used for meta-analysis of proportions and heterogeneity was estimated using Higgins' I

resultsQuantitative synthesis included 19 studies and 417 cases of CHMCF. Diagnosis was made using ultrasound in 76.0% (95% CI, 58.5-90.6%) of cases and occurred in the first trimester in 52.7% (95% CI, 34.0-71.0%). Symptoms at diagnosis were present in 80.5% (95% CI, 66.1-92.3%) of cases, with vaginal bleeding being the most common symptom both at diagnosis and later in pregnancy. The pooled proportion of elective pregnancy termination was 48.8% (95% CI, 32.7-65.1%), with 6.2% (95% CI, 1.0-13.9%) due to maternal complications. The pooled proportion of live births was 46.5% (95% CI, 36.1-57.1%), with most being delivered by Cesarean section (71.2% (95% CI, 42.4-94.4%)). Preterm birth (< 37 weeks) occurred in 67.8% (95% CI, 44.7-88.1%) of cases, very preterm birth (< 32 weeks) in 12.4% (95% CI, 0.2-33.9%) and miscarriage (fetal death < 24 weeks) in 32.7% (95% CI, 26.1-39.6%). Pre-eclampsia was present in 17.8% (95% CI, 5.9-32.7%) of cases and postpartum hemorrhage occurred in 42.7% (95% CI, 5.1-84.8%). A small-for-gestational-age neonate (birth weight < 10

conclusionsPregnancies with CHMCF present a high risk of maternal, obstetric and neonatal complications, including miscarriage, pre-eclampsia, small-for-gestational age, postpartum hemorrhage and preterm birth. The risk of developing gestational trophoblastic neoplasia was not clearly mitigated by early pregnancy termination. Early diagnosis, referral to a maternal-fetal medicine unit with expertise in trophoblastic disorders and extensive implementation of screening protocols for preterm birth and pre-eclampsia are recommended to facilitate timely intervention aimed at outcome improvement. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Indexed as

FetusHydatidiform MoleUterine NeoplasmsFemaleHumansPregnancyPregnancy OutcomeUltrasonography, Prenatalcomplete hydatidiform molegestational trophoblastic neoplasiameta‐analysismolar pregnancyoncological outcomepre‐eclampsiapregnancy outcomepreterm birthtwin pregnancy

Identifiers

PMID41066778
PMCPMC12951261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.